Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Shattuck Labs (NASDAQ:STTK) in a report published on Monday morning, Marketbeat reports. The brokerage issued an overweight rating on the stock.

Other equities analysts have also issued reports about the stock. Wall Street Zen raised shares of Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Piper Sandler started coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price objective for the company. Needham & Company LLC started coverage on shares of Shattuck Labs in a research report on Friday, March 6th. They issued a “buy” rating and a $25.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Finally, HC Wainwright increased their price objective on shares of Shattuck Labs from $6.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Shattuck Labs Stock Down 0.3%

Shares of Shattuck Labs stock opened at $7.72 on Monday. The firm has a market capitalization of $583.48 million, a P/E ratio of -10.03 and a beta of 1.28. The company has a 50 day moving average price of $6.01 and a 200 day moving average price of $4.08. Shattuck Labs has a 52 week low of $0.71 and a 52 week high of $8.33.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of ($1.00) million during the quarter, compared to analysts’ expectations of $0.17 million. As a group, research analysts anticipate that Shattuck Labs will post -0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Shattuck Labs

A number of institutional investors have recently bought and sold shares of the business. Turtle Creek Wealth Advisors LLC purchased a new position in Shattuck Labs during the 3rd quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the 3rd quarter worth approximately $38,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs during the 3rd quarter worth approximately $46,000. Mallini Complete Financial Planning LLC purchased a new position in Shattuck Labs during the 4th quarter worth approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new position in Shattuck Labs during the 4th quarter worth approximately $85,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.